NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDEverolimus Afinitor® Malignant disease and immunosuppression, Protein kinase inhibitors, 08.01.05
Non Formulary items found
Status Description Section
 EVEROLIMUS Tablets 250 micrograms,750 micrograms  Unlicensed Medicines / Significant off-label use, Unlicensed Medicines, 20
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Everolimus Everolimus Immune System, Antineoplastic Drugs, Protein Kinase Inhibitors
Immune System Disorders And Transplantation
Everolimus Everolimus Malignant Disease, Antineoplastic Drugs, Protein Kinase Inhibitors
Targeted Therapy Responsive Malignancy
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA348: Everolimus for preventing organ rejection in liver transplantation
NICE TA421: Everolimus with Exemestane for treating advanced breast cancer after endocrine therapy
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma